


# Pharmaceutical Cost Reports

Fully Insured Individual and Group Coverage  
(Excludes self-funded insured health groups)


## 2020 Q2 RX Summary by Generic, Brand, and Over the Counter

	Count	Percent Of Claims	Allowed Amt	% of Dollar Volume
Generic	3,059,192	78%	\$ 68,895,056.69	13%
Brand	824,575	21%	\$ 445,640,343.78	86%
OTC	32,311	1%	\$ 2,240,216.67	0%
	3,916,078		\$ 516,775,617.14	

Percent of Claims



Percent of Dollar Volume



## 2020 Q2 Top 10 Drug Categories

Drug Category	Charged	Allowed	Paid	Member Responsibility
Diabetic Therapies	\$ 80,748,931.05	\$ 61,483,119.12	\$ 54,538,700.15	\$ 6,860,303.83
Therapies for: Transplant Rejection, Arthritis, Autoimmune Diseases	\$ 72,886,018.53	\$ 57,164,397.24	\$ 54,153,883.17	\$ 2,733,967.21
Cancer Therapies	\$ 32,619,305.27	\$ 22,182,870.34	\$ 20,955,560.15	\$ 1,188,851.11
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 26,767,219.80	\$ 18,747,933.71	\$ 16,043,578.72	\$ 2,670,164.03
Asthma/Breathing Therapies	\$ 19,532,755.37	\$ 14,738,582.99	\$ 11,726,753.36	\$ 2,995,902.54
Therapies for: Alcohol Dependence, ADHD/Mental Alertness, Appetite Suppression, Neuromuscular Abnormalities, Glaucoma, Increase Bladder/Intestinal Functions	\$ 18,840,681.28	\$ 12,319,446.84	\$ 9,395,033.26	\$ 2,913,300.52
Therapies for: Fertility, Contraceptives, Anemia, Osteoporosis, Weight Loss, Excessive Hair Growth, Uterine Bleeding, Hormone-Dependent Tumors	\$ 15,653,416.64	\$ 10,253,207.28	\$ 8,160,248.36	\$ 2,125,427.17
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 12,537,640.40	\$ 10,198,039.41	\$ 9,498,713.26	\$ 495,467.06
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 12,740,735.00	\$ 9,343,249.41	\$ 7,709,495.99	\$ 1,630,036.06
Pain Therapies	\$ 22,146,426.19	\$ 7,451,995.30	\$ 5,610,802.30	\$ 1,839,483.47

**2020 Q2 Top 30 Drugs by Average Dollar Volume \***

<b>Trade Name</b>	<b>RX Type</b>	<b>Average Day Supply</b>	<b>Average Charged</b>	<b>Average Allowed</b>	<b>Average Paid</b>	<b>Average Member Responsibility</b>
HAEGARDA C1 ESTERASE INHIBITOR SUBCUTANEOUS HUMAN	BRAND	29	\$ 78,773.59	\$ 55,971.16	\$ 55,946.62	\$ 24.55
KORLYM	BRAND	30	\$ 43,399.78	\$ 43,399.78	\$ 43,085.49	\$ 314.29
PROCYSBI	BRAND	30	\$ 38,576.67	\$ 33,665.22	\$ 33,228.47	\$ 436.75
KALYDECO	BRAND	28	\$ 29,651.36	\$ 24,008.71	\$ 23,892.57	\$ 116.14
TRIKAFTA	BRAND	27	\$ 28,702.28	\$ 23,409.93	\$ 22,995.98	\$ 404.39
ORENITRAM	BRAND	27	\$ 39,780.00	\$ 22,541.99	\$ 22,322.53	\$ 219.46
SYMDEKO	BRAND	28	\$ 26,541.21	\$ 21,547.39	\$ 20,770.33	\$ 773.73
ORKAMBI	BRAND	28	\$ 25,103.08	\$ 21,228.09	\$ 20,718.31	\$ 494.62
STELARA	BRAND	39	\$ 24,800.71	\$ 20,625.82	\$ 20,115.72	\$ 456.52
PALYNZIQ	BRAND	29	\$ 22,008.46	\$ 19,684.94	\$ 19,013.06	\$ 671.88
POMALYST	BRAND	28	\$ 21,866.38	\$ 18,180.33	\$ 17,807.50	\$ 372.83
CABOMETYX	BRAND	26	\$ 21,226.57	\$ 17,622.70	\$ 17,302.33	\$ 320.37
TAGRISO	BRAND	30	\$ 20,720.37	\$ 16,021.06	\$ 15,864.65	\$ 156.41
REVLIMID	BRAND	26	\$ 19,201.12	\$ 15,946.72	\$ 15,793.91	\$ 152.81
BOSULIF	BRAND	30	\$ 18,807.53	\$ 15,503.05	\$ 15,503.05	\$ -
SKYRIZI	BRAND	40	\$ 20,194.91	\$ 16,588.05	\$ 15,438.32	\$ 1,120.40
INLYTA	BRAND	26	\$ 18,410.89	\$ 15,010.62	\$ 14,471.36	\$ 330.45
AFINITOR	BRAND	26	\$ 17,738.24	\$ 15,103.94	\$ 14,254.00	\$ 849.94
XYREM	BRAND	28	\$ 15,637.33	\$ 14,165.72	\$ 13,800.06	\$ 365.66
JYNARQUE	BRAND	27	\$ 17,774.62	\$ 14,118.97	\$ 13,761.24	\$ 351.43
KUVAN	BRAND	30	\$ 15,751.98	\$ 13,509.83	\$ 13,038.28	\$ 471.55
KISQALI	BRAND	26	\$ 15,327.42	\$ 12,819.80	\$ 12,814.54	\$ 5.26
ALECENSA	BRAND	24	\$ 16,110.00	\$ 12,661.23	\$ 12,604.30	\$ 56.93
JAKAFI	BRAND	29	\$ 15,251.77	\$ 12,739.40	\$ 12,581.43	\$ 157.97
IBRANCE	BRAND	27	\$ 14,689.24	\$ 12,406.66	\$ 12,241.16	\$ 165.50
BRAFTOVI	BRAND	30	\$ 14,678.90	\$ 12,326.20	\$ 12,224.98	\$ 101.22
TASIGNA	BRAND	24	\$ 14,594.90	\$ 12,509.23	\$ 12,210.87	\$ 296.96
ZEJULA	BRAND	27	\$ 15,566.89	\$ 12,092.93	\$ 12,092.93	\$ -

MAVYRET	BRAND	28	\$ 15,840.23	\$ 13,041.79	\$ 11,917.70	\$ 578.64
PROMACTA	BRAND	29	\$ 15,280.21	\$ 12,016.95	\$ 11,711.14	\$ 275.81

\*To be included in this table, at least 20 prescriptions for the drug must exist in the database.

**2020 Q2 Top 30 Drugs by Total Dollar Volume \***

<b>TradeName</b>	<b>RX Type</b>	<b>Total Charged</b>	<b>Total Allowed</b>	<b>Total Paid</b>	<b>Total Member Responsibility</b>
HUMIRA	BRAND	\$ 54,161,194.43	\$ 43,544,730.56	\$ 40,730,960.40	\$ 2,602,802.89
STELARA	BRAND	\$ 23,287,869.36	\$ 19,367,646.33	\$ 18,888,659.87	\$ 428,669.40
ATORVASTATIN CALCIUM	GENERIC	\$ 18,081,672.62	\$ 791,361.35	\$ 267,329.70	\$ 525,494.57
ENBREL	BRAND	\$ 16,451,083.98	\$ 13,304,580.33	\$ 12,334,361.44	\$ 970,218.89
NOVOLOG	BRAND	\$ 12,739,326.05	\$ 10,091,076.92	\$ 9,284,479.27	\$ 772,402.78
NORDITROPIN	BRAND	\$ 11,336,246.62	\$ 8,785,201.89	\$ 8,242,055.81	\$ 529,118.68
TRULICITY	BRAND	\$ 11,240,881.28	\$ 8,882,005.12	\$ 8,059,167.58	\$ 810,025.59
TRIKAFTA	BRAND	\$ 10,562,440.00	\$ 8,614,855.05	\$ 8,462,518.80	\$ 148,816.25
OZEMPIC	BRAND	\$ 10,322,935.55	\$ 8,189,496.31	\$ 7,445,568.70	\$ 740,995.97
VYVANSE	BRAND	\$ 9,924,859.91	\$ 7,859,049.48	\$ 5,969,862.04	\$ 1,884,529.22
OMEPRAZOLE	GENERIC	\$ 9,661,973.54	\$ 418,698.47	\$ 40,024.19	\$ 379,219.50
COSENTYX	BRAND	\$ 9,576,949.39	\$ 7,392,739.50	\$ 6,809,716.97	\$ 524,783.37
OTEZLA	BRAND	\$ 9,272,301.47	\$ 7,443,802.75	\$ 6,614,823.15	\$ 800,664.43
VICTOZA	BRAND	\$ 8,599,645.09	\$ 6,762,400.15	\$ 6,292,410.35	\$ 455,335.99
ARIPIRAZOLE	GENERIC	\$ 8,568,405.84	\$ 247,846.39	\$ 102,622.58	\$ 145,286.80
ROSUVASTATIN CALCIUM	GENERIC	\$ 7,205,705.44	\$ 303,140.42	\$ 124,339.28	\$ 179,490.27
JARDIANCE	BRAND	\$ 6,732,675.50	\$ 5,321,516.67	\$ 4,608,795.92	\$ 708,882.00
TRESIBA	BRAND	\$ 6,598,984.47	\$ 5,152,014.72	\$ 4,619,650.33	\$ 530,509.32
DUPIXENT	BRAND	\$ 6,482,546.98	\$ 5,101,059.66	\$ 4,345,472.11	\$ 663,851.80
PANTOPRAZOLE SODIUM	GENERIC	\$ 6,399,576.22	\$ 319,851.38	\$ 37,744.49	\$ 282,558.18
ELIQUIS	BRAND	\$ 6,204,835.17	\$ 4,890,129.44	\$ 4,065,344.21	\$ 822,798.02
TECFIDERA	BRAND	\$ 6,146,470.63	\$ 4,974,384.80	\$ 4,682,809.76	\$ 270,308.86
JANUVIA	BRAND	\$ 5,440,996.28	\$ 4,255,675.03	\$ 3,762,852.95	\$ 492,828.63
VENLAFAXINE HYDROCHLORIDE	GENERIC	\$ 5,394,843.42	\$ 763,648.63	\$ 365,529.24	\$ 397,762.39
SYMBICORT	BRAND	\$ 5,273,212.72	\$ 4,133,611.00	\$ 3,206,491.24	\$ 926,594.82
BIKTARVY	BRAND	\$ 5,226,818.29	\$ 4,302,494.37	\$ 3,278,384.26	\$ 1,024,010.65
REVLIMID	BRAND	\$ 5,145,900.33	\$ 4,273,720.46	\$ 4,232,768.02	\$ 40,952.44

XARELTO	BRAND	\$ 5,112,454.06	\$ 4,013,974.24	\$ 3,337,275.58	\$ 675,002.73
ONDANSETRON	GENERIC	\$ 5,055,644.98	\$ 172,620.40	\$ 40,517.88	\$ 133,082.90
MONTELUKAST SODIUM	GENERIC	\$ 4,916,602.49	\$ 253,495.23	\$ 52,496.18	\$ 201,466.76

\* To be included in this table, at least 20 prescriptions for the drug must exist in the database.

## 2020 Q2 RX Counts by Plan / Product Type

Plan Type	Plan Description	Product Type	Product Description	RXcount	Charged Per Script	Allowed Per Script	Paid Per Script	Mbr Resp Per Script
2	PPO	1	Medical/Health	2,671,394	\$ 292.10	\$ 158.52	\$ 138.41	\$ 19.74
7	Qualified High Deductible PI	1	Medical/Health	507,804	\$ 333.64	\$ 182.04	\$ 126.44	\$ 54.94
4	POS	1	Medical/Health	250,265	\$ 292.66	\$ 157.05	\$ 139.38	\$ 17.67
3	HMO	1	Medical/Health	43,229	\$ 464.74	\$ 242.66	\$ 219.96	\$ 22.78
7	Qualified High Deductible PI	2	Ancillary Drug	4	\$ 115.97	\$ 18.46	\$ 3.03	\$ 15.43
4	POS	2	Ancillary Drug	1	\$ 10.84	\$ 5.89	\$ -	\$ 5.89

## 2020 Q2 PMPM RX Costs

	Member Months	Allowed	Average PMPM
Age <= 14	491,641	\$ 29,472,483.50	\$ 59.95
Age 15-24	432,223	\$ 49,716,312.07	\$ 115.02
Age 25-44	962,736	\$ 144,844,569.89	\$ 150.45
Age 45-64	990,999	\$ 295,606,706.87	\$ 298.29

## Average Allowed Charge PMPM by Age Group

